My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Emergent BioSolutions Inc. Common Stock (NY:EBS)

9.795 +0.195 (+2.03%)
Streaming Delayed Price Updated: 12:03 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Emergent BioSolutions Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025
From Emergent BioSolutions
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone
From Emergent BioSolutions
Via GlobeNewswire
Earnings Scheduled For August 6, 2025
 
Via Benzinga
A Preview Of Emergent BioSolutions's Earnings
 
Via Benzinga
3 Small-Cap Stocks to Watch After the Fed’s Rate Cuts
Discover three low P/E small-cap stocks with bullish analyst sentiment and growth potential in a lower interest rate environment 
Via MarketBeat
Topics Economy
Emergent BioSolutions Stock Rises After Receiving Fresh International Purchase Orders: Retail Says Stock Is ‘Significantly Undervalued’
The order encompasses multiple product offerings within Emergent’s medical countermeasures business, including countermeasures for threats posed by Smallpox, Anthrax, and Botulism. 
Via Stocktwits
Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International Overdose Awareness Day
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions to Participate in Upcoming Investor Conferences
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Supports Voices for Awareness and Facing Fentanyl Now on August 21, 2025 for National Fentanyl Prevention and Awareness Day™
From Emergent BioSolutions
Via GlobeNewswire
Big Rallies Brewing? 3 Analyst Favorites to Watch Closely
Despite share price pops after earnings, SKYT, EBS, and BLZE may still have room to rally further, as each firm has garnered strong analyst support. 
Via MarketBeat
Thursday's session: top gainers and losers
Stay up-to-date with the latest market trends one hour before the close of the markets on Thursday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Traders are paying attention to the gapping stocks in Thursday's session.
Let's have a look at the gap up and gap down stocks in today's session. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Emergent BioSolutions Reports Second Quarter 2025 Financial Results
From Emergent BioSolutions
Via GlobeNewswire
New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox
Ongoing mpox outbreak continues to be a global health threat and is driving need for greater therapeutic research and innovation 
From Emergent BioSolutions
Via GlobeNewswire
Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Stock Rises After New US Order For Smallpox Complication Therapy
The company also secured a $62.4 million modification to its botulism antitoxin supply contract and recently expanded its NARCANDirect platform to include a new opioid overdose reversal spray. 
Via Stocktwits
Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate
Starting July 1, 2025, additional opioid overdose response tools will be available to continue addressing evolving patient and customer needs to combat public health crisis 
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Bolster U.S. Biodefense Supply
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Announces Addition to Russell 3000® Index
From Emergent BioSolutions
Via GlobeNewswire
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:PFE),(NASDAQ:COLL),(NYSE:TEVA),(NYSE:EBS) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030
From FN Media Group LLC
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.